Form 4: Yi Sang reports sale transactions in ZBH

Rhea-AI Filing Summary

Yi Sang reported open-market sale transactions in a Form 4 filing for ZBH. The filing lists transactions totaling 1,000 shares at a weighted average price of $96.49 per share. Following the reported transactions, holdings were 17,670 shares.

Insider Trade Summary

Net Seller: 1,000 shares ($96,490)

Net Sell 1 txn

Insider Yi Sang

Role Group President, Asia Pacific

Sold 1,000 shs ($96K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,000	$96.49	$96K

Holdings After Transaction: Common Stock — 17,670 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Yi Sang

(Last) (First) (Middle)

345 E. MAIN STREET

(Street)

WARSAW IN 46580

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ZIMMER BIOMET HOLDINGS, INC. [ ZBH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Group President, Asia Pacific

3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/12/2026		S		1,000	D	$96.49	17,670(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Includes 86 shares acquired under the Employee Stock Purchase Plan on December 31, 2025.

	/s/ Matthew R. St. Louis, Attorney-in-Fact for Sang Yi (power of attorney previously filed)	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ZBH executive Sang Yi report?

Sang Yi reported selling 1,000 shares of Zimmer Biomet common stock in an open-market transaction. The sale occurred on February 12, 2026, at $96.49 per share, and was disclosed as a routine Form 4 insider trading report.

At what price did Sang Yi sell Zimmer Biomet (ZBH) shares?

Sang Yi sold 1,000 Zimmer Biomet shares at $96.49 per share. This was identified as an open-market sale and is documented in the insider trading report for the transaction dated February 12, 2026.

How many Zimmer Biomet (ZBH) shares does Sang Yi own after the sale?

After the reported sale, Sang Yi beneficially owns 17,670 Zimmer Biomet common shares directly. This total includes 86 shares that were acquired through the company’s Employee Stock Purchase Plan on December 31, 2025.

What is Sang Yi’s role at Zimmer Biomet (ZBH) in this Form 4?

In the filing, Sang Yi is identified as an officer of Zimmer Biomet with the title Group President, Asia Pacific. The reported stock transaction reflects trading in the company’s common stock by this senior executive.

Does the Form 4 note any shares from Zimmer Biomet’s Employee Stock Purchase Plan?

Yes. A footnote explains that the reported holdings include 86 shares acquired under Zimmer Biomet’s Employee Stock Purchase Plan on December 31, 2025, which form part of Sang Yi’s total 17,670 directly owned shares.